By admin 
The findings, unveiled during a highly anticipated Hot Line session at ESC Congress 2026, not only revealed an unexpected equivalence in observed event rates but also a striking difference in how consistently patients took their medication. Those advised to use statins based on visible calcium buildup in their coronary arteries were substantially more likely to follow their treatment recommendations, suggesting a powerful psychological component to patient compliance.
While these results suggest that heart scans could empower doctors to make more targeted treatment decisions, the trial did not definitively establish that the scan-guided approach was as effective as conventional risk assessment. This crucial distinction stems from statistical limitations within the study design, prompting researchers to call for additional, larger studies to determine whether coronary artery calcium (CAC) scoring truly offers a superior or at least equivalent strategy for preventing cardiovascular disease in the long term.
The Enduring Challenge of Predicting Heart Disease Risk
Cardiovascular disease (CVD) remains the world’s leading cause of illness, disability, and death, claiming millions of lives annually. Much of this devastating burden comes from atherosclerotic cardiovascular disease (ASCVD), a progressive condition where fatty deposits, known as plaque, accumulate inside arteries. This insidious process, often beginning silently decades before symptoms appear, hardens and narrows the arteries, restricting blood flow and increasing the critical risk of life-threatening events such as heart attacks (myocardial infarction) and ischemic strokes. Coronary artery disease, affecting the heart’s blood supply, and ischemic stroke, impacting brain blood flow, are two major manifestations of ASCVD.
Several well-established factors significantly increase the likelihood of developing ASCVD, including modifiable lifestyle choices like smoking, unhealthy diet, and physical inactivity, alongside medical conditions such as diabetes, high blood pressure (hypertension), and elevated cholesterol levels, particularly low-density lipoprotein cholesterol (LDL-C), often dubbed "bad cholesterol." For decades, doctors have relied on these factors to estimate an individual’s cardiovascular risk and determine whether preventive medications are appropriate.
Statins are among the most widely used and effective treatments for lowering this risk. These potent medications work primarily by inhibiting HMG-CoA reductase, an enzyme crucial for cholesterol production in the liver. This action dramatically reduces LDL-C levels, but statins also exert beneficial "pleiotropic" effects, including anti-inflammatory properties and plaque stabilization, further contributing to their protective effects against serious cardiovascular complications. Their efficacy in both primary prevention (preventing a first event) and secondary prevention (preventing subsequent events) has been rigorously demonstrated in numerous large-scale clinical trials.
However, despite their proven benefits, identifying precisely which patients stand to benefit most from statins remains a significant challenge. Current guidelines often recommend statins based on age, risk factor burden, and calculated risk scores. Yet, a substantial proportion of individuals who eventually experience a heart attack do not appear to be at particularly high risk under conventional screening methods. These "missed" patients represent a critical gap in preventive cardiology.
"For far too many patients, the first symptom of ASCVD is a heart attack," lamented Doctor Joseph B Muhlestein from the Intermountain Medical Center, Murray, USA, the Principal Investigator of the CorCal Outcomes trial. "Statins have been shown to be highly effective in the prevention of ASCVD; however, there is a major gap in risk assessment, statin initiation, and statin persistence." Muhlestein further elaborated that many people who suffer their first heart attack, particularly younger adults, would not previously have been classified as having enough cardiovascular risk to justify statin treatment by traditional metrics. This inherent limitation in predicting individual risk has prompted researchers to investigate whether directly examining the arteries for evidence of disease might provide more accurate and useful information.
Can Heart Calcium Scans Improve Statin Decisions?
The CorCal Outcomes trial was specifically designed to investigate two distinct approaches for determining which patients should be advised to begin statin therapy before experiencing a cardiovascular event. This primary prevention context is where the greatest uncertainty and potential for improvement lie.
The first approach relied on the pooled cohort equations (PCE), a widely utilized risk assessment tool in the United States. These equations estimate an individual’s 10-year risk of ASCVD using a combination of traditional factors such as age, sex, total and HDL cholesterol levels, systolic blood pressure, use of antihypertensive medication, diabetes status, and smoking status. The PCE provide a probabilistic estimate of future risk, guiding clinicians on when to initiate preventive therapies.
The second approach introduced coronary artery calcium (CAC) measurement, which offers a more direct, anatomical indication of plaque buildup in the arteries supplying the heart. This non-invasive measurement uses a specialized computed tomography (CT) scan to detect and quantify calcium deposits within the coronary arteries. Calcium accumulation is a hallmark of advanced atherosclerotic plaque, making it a highly sensitive and specific marker of underlying coronary artery disease, even in individuals who have not yet developed symptoms. The Agatston score, derived from these scans, quantifies the extent of calcium, with higher scores indicating greater plaque burden and thus higher risk.
Unlike traditional risk calculators, which estimate the likelihood of future cardiovascular problems based on personal characteristics and health measurements, calcium scans provide direct evidence of disease already present in the coronary arteries. This fundamental difference suggests that CAC scoring might offer a more precise risk stratification tool, especially for individuals whose traditional risk factors place them in an intermediate or borderline category. Researchers aimed to determine whether incorporating this direct evidence of disease into statin recommendations could lead to improved cardiovascular outcomes.
Nearly 5,800 Patients Put Both Methods to the Test
The CorCal Outcomes trial meticulously enrolled 5,772 patients from the Canyons and Desert regions served by Intermountain Health Care in the United States. To focus on primary prevention, eligible participants had no known history of ASCVD or diabetes and had not previously received statin therapy. This ensured that the study population represented individuals for whom statin initiation decisions are most challenging.
The study population had an average age of 64 years, reflecting the demographic where ASCVD risk becomes more pronounced. Women constituted a slight majority, accounting for 51% of the study participants, ensuring a balanced representation across genders.
Upon enrollment, eligible participants were randomly assigned (1:1) to one of two distinct groups. One group received statin treatment guidance based on their traditional cardiovascular risk scores, specifically derived from the pooled cohort equations. The other group received recommendations based on their coronary calcium scan results. A critical aspect of the trial design was that both patients and their physicians were informed of the treatment recommendations generated by the study protocol. However, the final decision about whether to start taking statins ultimately remained with the individual patients and their doctors, reflecting real-world clinical practice and shared decision-making.
The researchers then meticulously tracked major cardiovascular events (MACE) as their primary outcome measure. This comprehensive combined outcome included all-cause mortality (death from any cause), myocardial infarction (heart attack), stroke, and arterial revascularization procedures (such as angioplasty or bypass surgery to restore blood flow through narrowed or blocked arteries). The mean follow-up period for the study was 4.2 years.
Heart Scans Led to Far Fewer Statin Recommendations, Yet Observed Outcomes Were Similar
After an average follow-up of 4.2 years, the core finding of the CorCal Outcomes trial was both surprising and thought-provoking: major cardiovascular events occurred at exactly the same observed rate in both groups. A total of 2.7% of patients in each group experienced one of the events included in the study’s primary outcome (all-cause mortality, myocardial infarction, stroke, or arterial revascularization). The estimated relative risk over time, expressed as a hazard ratio, was also nearly identical (0.99; 95% confidence interval 0.71 to 1.38). This result met the statistical criterion of p=0.045 for noninferiority, meaning the CAC-guided strategy was not statistically worse than the PCE-guided strategy.
However, this statistical noninferiority result did not unequivocally establish that the two strategies were truly equally effective in a broader clinical sense. The study failed to meet its predetermined statistical requirement for demonstrating that the calcium scan approach was not meaningfully worse than conventional risk assessment with a sufficiently narrow margin. This limitation stemmed primarily from fewer participants experiencing major cardiovascular events than the investigators had anticipated. With a lower-than-expected event rate, the trial had reduced statistical power to definitively rule out a small, but clinically significant, difference between the two approaches.
Despite this nuance, a truly remarkable difference emerged in how frequently patients were advised to begin taking statins. Participants evaluated using traditional risk scores (PCE-guided group) received recommendations to start statin therapy more than three times as often as those whose decisions were guided by coronary calcium measurements (CAC-guided group). This disparity is profound: the traditional risk assessment approach led to significantly more individuals being recommended statins. Yet, despite this substantial difference in treatment recommendations, both groups experienced the same observed rate of major cardiovascular events during the follow-up period. This raises critical questions about over-prescription and the efficiency of statin initiation under traditional guidelines.
A Surprising Difference in Statin Adherence
Perhaps the most intriguing and potentially impactful finding of the CorCal Outcomes trial involved whether patients actually followed their prescribed treatment recommendations. Among those advised to take statins, patients whose recommendations were based on calcium scans were dramatically more likely to adhere to their medication regimen than those assessed using traditional cardiovascular risk factors.
The difference in adherence rates was substantial and statistically significant: 62% adherence in the CAC-guided group versus only 23% in the PCE-guided group. In other words, patients recommended statins based on visible evidence of calcium buildup in their own arteries were approximately 2.7 times as likely to consistently take their medication.
One compelling possible explanation for this stark difference is the "seeing is believing" phenomenon. Receiving a numerical risk score based on abstract factors might be less impactful than seeing a personalized image of one’s own coronary arteries showing tangible evidence of atherosclerotic plaque. This direct, visual confirmation of disease may serve as a powerful motivator, fostering a greater sense of urgency and personal responsibility to engage with preventive therapy. However, the trial did not explicitly establish the psychological mechanisms behind why adherence differed so dramatically between the groups. It simply observed the outcome.
These findings raise the tantalizing possibility that coronary calcium scans could influence not only which patients receive statin recommendations, but also whether those patients consistently take the medications, a factor known to be paramount for statin effectiveness. Improved adherence, if sustained over a lifetime, could translate into substantial improvements in long-term cardiovascular outcomes.
What the Findings Mean for Heart Disease Prevention
Despite these potentially important differences in prescription rates and adherence, the researchers emphasized that the study, due to its statistical limitations, could not definitively establish whether calcium scan-guided treatment provides cardiovascular protection comparable to traditional risk assessment over the long term. The primary limitation was that fewer participants experienced major cardiovascular events than the investigators had anticipated. With fewer events to analyze, the trial had less statistical power to determine whether a meaningful difference existed between the two approaches, particularly regarding the non-inferiority hypothesis.
"The power of the study to detect a difference was reduced by the lower-than-expected event rates and we did not demonstrate noninferiority between the groups," stated Doctor Muhlestein. He concluded, however, that "The study did provide important hypothesis-generating insights into the efficiency of statin initiation and adherence when decisions are based on CAC scoring. Taken together, our data could be used to plan an additional well-powered randomized trial comparing CAC with current risk factor-based algorithms."
The CorCal Outcomes findings are thus pivotal not as a definitive answer, but as a critical stepping stone. They provide invaluable data that may help researchers design future trials capable of determining whether coronary calcium scans can improve the efficiency of statin prescribing—potentially reducing unnecessary prescriptions—without compromising overall cardiovascular protection. Such future trials would need larger sample sizes and longer follow-up periods to capture a sufficient number of cardiovascular events and provide more conclusive evidence.
It’s also important to contextualize these findings within existing clinical guidelines. Current European recommendations already recognize a potential role for CAC measurements. Specifically, the 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidemias recommends considering increased coronary calcium scores, when available, as an additional factor in cardiovascular risk assessment. This guidance applies particularly to people at moderate cardiovascular risk or those whose estimated risk falls near the threshold at which preventive medication would normally be recommended. For these individuals, evidence of calcium buildup may provide crucial additional information, helping doctors make more informed and personalized decisions when the need for statin therapy is uncertain.
The CorCal Outcomes findings add a compelling new dimension to this discussion by suggesting that heart scans may also profoundly influence how faithfully patients follow treatment recommendations. Whether that advantage in adherence translates into better long-term cardiovascular outcomes and a more efficient, patient-centered approach to heart disease prevention remains an important and exciting question for future research. The path towards truly personalized and effective cardiovascular prevention continues to evolve, with CAC scoring emerging as a powerful tool in the clinician’s arsenal.
